A case study of a woman with multifocal GBM demonstrated a complete response of one of the tumour sites to osimertinib treatment; however, the disease progressed at the other tumour site, likely due to the heterogeneous nature of the patient’s EGFR mutation status [71]. This evidence concerns the gene EGFR and glioblastoma.